[go: up one dir, main page]

WO2001015710A3 - Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme - Google Patents

Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme Download PDF

Info

Publication number
WO2001015710A3
WO2001015710A3 PCT/US2000/024194 US0024194W WO0115710A3 WO 2001015710 A3 WO2001015710 A3 WO 2001015710A3 US 0024194 W US0024194 W US 0024194W WO 0115710 A3 WO0115710 A3 WO 0115710A3
Authority
WO
WIPO (PCT)
Prior art keywords
human immunodeficiency
treatment
immunodeficiency diseases
diseases
reconstitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/024194
Other languages
English (en)
Other versions
WO2001015710A2 (fr
Inventor
Ashot P Khatchatrian
Robert G Khatchatrian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP00961512A priority Critical patent/EP1189636A2/fr
Priority to AU73454/00A priority patent/AU7345400A/en
Publication of WO2001015710A2 publication Critical patent/WO2001015710A2/fr
Publication of WO2001015710A3 publication Critical patent/WO2001015710A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention a trait à une méthode de traitement d'états pathologiques d'immunodéficience chez l'homme consistant à administrer des solutés salins aqueux électroactivés et à reconstituer ensuite une microflore saine.
PCT/US2000/024194 1999-09-01 2000-09-01 Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme Ceased WO2001015710A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00961512A EP1189636A2 (fr) 1999-09-01 2000-09-01 Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme
AU73454/00A AU7345400A (en) 1999-09-01 2000-09-01 A method of treatment of human immunodeficiency diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU99118610A RU2149633C1 (ru) 1999-09-01 1999-09-01 Способ лечения иммунодефицитных состояний организма
RU99118610 1999-09-01

Publications (2)

Publication Number Publication Date
WO2001015710A2 WO2001015710A2 (fr) 2001-03-08
WO2001015710A3 true WO2001015710A3 (fr) 2002-01-17

Family

ID=20224393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024194 Ceased WO2001015710A2 (fr) 1999-09-01 2000-09-01 Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme

Country Status (4)

Country Link
EP (1) EP1189636A2 (fr)
AU (1) AU7345400A (fr)
RU (1) RU2149633C1 (fr)
WO (1) WO2001015710A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939568B2 (en) 2001-04-23 2005-09-06 Nucryst Pharmaceuticals Corp. Treatment of inflammatory skin conditions
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US7078060B2 (en) 2000-07-27 2006-07-18 Nucryst Pharmaceuticals Corp. Solutions and aerosols of metal-containing compounds
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7470437B2 (en) 2000-07-27 2008-12-30 Nucryst Pharmaceuticals Corp. Methods of treating conditions with a metal-containing material

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2178300C1 (ru) * 2000-08-17 2002-01-20 Омская государственная медицинская академия Способ лечения больных полипозом толстого кишечника
US7090839B2 (en) 2000-09-01 2006-08-15 Hidden Valley, N.V. Method of treatment of human immunodeficiency diseases
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
RU2209072C2 (ru) * 2001-09-25 2003-07-27 Орловский Евгений Владимирович Антивирусная композиция для лечения вич-инфицированных больных с высокой вирусной нагрузкой
RU2216334C1 (ru) * 2002-02-20 2003-11-20 Роговин Всеволод Викторович Солевой раствор роговина в.в.
JP2005120084A (ja) * 2003-09-25 2005-05-12 Hoshizaki Electric Co Ltd 免疫賦活剤、その生成方法および生成装置
RU2290162C2 (ru) * 2004-06-22 2006-12-27 Ашот Папикович Хачатрян Способ комплексного оздоровления пациента и устройство для его реализации
DE102004049338A1 (de) * 2004-07-24 2006-02-16 Behrens, Stephan Verwendung eines Inhalators und dem mit einem Inhalator hergestellen salzhaltigen Aerosol
RU2271209C1 (ru) * 2004-08-12 2006-03-10 Сергей Борисович Авакимян Способ лечения злокачественных опухолей
DE602004006258T3 (de) * 2004-08-24 2013-08-29 Nutricia N.V. Nahrungszusammensetzung die unverdauliche Transgalaktooligosaccharide sowie verdauliche Galaktose-Saccharide enthält
KR20070057873A (ko) * 2004-09-27 2007-06-07 호시자키 덴키 가부시키가이샤 면역부활제, 그 생성 방법 및 생성 장치
RU2363480C2 (ru) * 2006-11-24 2009-08-10 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" Антидепрессивное средство
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
RU2408377C2 (ru) * 2008-03-20 2011-01-10 Ашот Папикович Хачатрян Способ поддержания жизнедеятельности организма больного, отягощенного онкологическим процессом
JP4524715B2 (ja) * 2008-07-14 2010-08-18 広島化成株式会社 ミネラル含有加水素水およびその製造方法
RU2538086C2 (ru) * 2013-01-29 2015-01-10 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Новосибирский Государственный Педагогический Университет" Способ лечения сахарного диабета, осложненного сопутствующими заболеваниями
EP3010853B1 (fr) 2013-06-17 2023-02-22 Nanocomp Technologies, Inc. Agents exfoliants-dispersants pour nanotubes, faisceaux et fibres
US11434581B2 (en) 2015-02-03 2022-09-06 Nanocomp Technologies, Inc. Carbon nanotube structures and methods for production thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013532A2 (fr) * 1991-02-04 1992-08-20 Joseph Chayen Derives de naphtoquinone utilises pour traiter les inflammations chroniques
RU2077886C1 (ru) * 1996-06-25 1997-04-27 Раиса Николаевна Сумерина Способ лечения инкурабельных больных
RU2092167C1 (ru) * 1995-02-22 1997-10-10 Хачатрян Ашот Папикович Способ лечения дисбактериоза кишечника
RU2122397C1 (ru) * 1997-12-18 1998-11-27 Ашот Папикович Хачатрян Способ получения косметического средства для ухода за кожей

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2089194C1 (ru) * 1995-12-14 1997-09-10 Гинтер Елена Константиновна Способ лечения хронической генерализованной вирусной инфекции

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013532A2 (fr) * 1991-02-04 1992-08-20 Joseph Chayen Derives de naphtoquinone utilises pour traiter les inflammations chroniques
RU2092167C1 (ru) * 1995-02-22 1997-10-10 Хачатрян Ашот Папикович Способ лечения дисбактериоза кишечника
RU2077886C1 (ru) * 1996-06-25 1997-04-27 Раиса Николаевна Сумерина Способ лечения инкурабельных больных
RU2122397C1 (ru) * 1997-12-18 1998-11-27 Ашот Папикович Хачатрян Способ получения косметического средства для ухода за кожей

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199746, Derwent World Patents Index; Class B06, AN 1997-501203, XP002174820 *
DATABASE WPI Section Ch Week 199822, Derwent World Patents Index; Class B04, AN 1998-249313, XP002174819 *
DATABASE WPI Section Ch Week 200015, Derwent World Patents Index; Class B07, AN 2000-170048, XP002174818 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US7078060B2 (en) 2000-07-27 2006-07-18 Nucryst Pharmaceuticals Corp. Solutions and aerosols of metal-containing compounds
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7470437B2 (en) 2000-07-27 2008-12-30 Nucryst Pharmaceuticals Corp. Methods of treating conditions with a metal-containing material
US6939568B2 (en) 2001-04-23 2005-09-06 Nucryst Pharmaceuticals Corp. Treatment of inflammatory skin conditions
US6989156B2 (en) 2001-04-23 2006-01-24 Nucryst Pharmaceuticals Corp. Therapeutic treatments using the direct application of antimicrobial metal compositions
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US7087249B2 (en) 2001-04-23 2006-08-08 Nucryst Pharmaceuticals Corp. Treatment of mucosal membranes
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases

Also Published As

Publication number Publication date
WO2001015710A2 (fr) 2001-03-08
RU2149633C1 (ru) 2000-05-27
EP1189636A2 (fr) 2002-03-27
AU7345400A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
WO2001015710A3 (fr) Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme
AU2001249881A1 (en) Method of treating the heart
AU8880701A (en) Cardiac arrhythmia treatment methods
CA2272584A1 (fr) Nouveaux derives de pyrazole substitues pour le traitement de maladies cardio-vasculaires
WO2002053101A3 (fr) Procede de traitement de troubles fibrogenes et autres symptomes de type ivc
WO2001045679A3 (fr) Utilisation d'agents chimiotherapeutiques
AU5114601A (en) Method for the treatment of dermal lesions caused by envenomation
WO2002030508A3 (fr) Electrode nerveuse a manchon
WO2001060347A3 (fr) Methode de traitement des douleurs oculaires
WO2000059487A3 (fr) Utilisation de flupirtine pour le traitement de la fibromyalgie et d'affections associees a la fibromyalgie
ZA200107122B (en) Treatment of acne using lipoic acid.
IL145068A0 (en) The use of glycine betaine to prepare a pharmaceutical composition
GB2316091B (en) Electrolytic treatment of aqueous salt solutions
WO2000064474A8 (fr) Methode de traitement de la fibrose utilisant un antagoniste de la sous-unite alpha-4 de l'integrine
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU2000258352A1 (en) Acupuncture points stimulation for treating various diseases
WO2001018004A3 (fr) PYRAZOLO[4,3-d]PYRIMIDINES
EP1440691A3 (fr) Traitement des troubles neurotiques
ZA200306124B (en) Method of treating of demyelinating diseases or conditions.
IL153733A0 (en) A new use for deferiprone
WO2002043715A3 (fr) Utilisation de composes 1-phenyl-3-dimethylamino-propane pour traiter l'incontinence urinaire
WO2000059940A3 (fr) Gene et proteine lies au facteur de croissance d'origine plaquettaire
WO2002043714A3 (fr) Utilisation de composes 6-dimethylaminomethyle-1-phenyl-cyclohexane substitues pour traiter l'incontinence urinaire
WO2002043712A3 (fr) Utilisation de composes 6-dimethylaminomethyle-1-phenyl-cyclohexane pour traiter l'incontinence urinaire
AU2900100A (en) Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000961512

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000961512

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000961512

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP